Publications
[If you would like any references to publications posted here, please e-mail Murrium Ahmad]
Partner 1a(Rees)
Matharoo-Ball B, Ratcliffe L, Lancashire L, Ugurel S, Rees RC, Schadendorf D, Ball G, Miles A, Creaser C. Diagnostic biomarkers using novel methods in serum using MALDI-TOF mass spectrometry-bioinformatic approaches. (manuscript in press.)
Miles AK, Matharoo-Ball B, Li G, Ahmad M, Rees RC. (2006). The identification of human tumour antigens: current status and future developments. Cancer Immunol Immunother. (Epub ahead of print) Jan 12; 1-8.
[ Back to top ]
Partner 1b(Dodi)
Stanley SM, Dodi IA, Evans CR, Paston SJ, Rees RC, Percival C (2005). Layer Guided-Acoustic Plate Mode Biosensors for monitoring MHC-peptide interactions. Biosensors & Bioelectronics, (manuscript in press)
[ Back to top ]
Partner 4 (Kiessling)
Miller AM, Egevad L, Lundberg K, Ozenci V, Banham AH, Hellstrom M and Pisa P. CD4+/CD25+ high T cells enriched in the peripheral blood and tumour tissue of patients with prostate cancer (Submitted)
Miller AM, Pisa P (2005) Tumour escape mechanisms and prostate cancer. Cancer Immunol Immunother. (In press)
[ Back to top ]
Partner 5 (Jotereau)
Benlalam H, Vignard V, Khammari A, Bonin A, Godet Y, Jotereau F, Dreno B and Labarriere N. Dominance of MELAN-A/MART-1 specific lymphocytes in TIL infused to melanoma patients who remained relapse-free after immunotherapy. (Submitted.)
Vignard V, Lemercier B, Lim A, Pandolfino MC, Guilloux Y, Khammari A, Rabu C, Echasserieau K, Lang F, Gougeon ML, Dreno B, Jotereau F and Labarriere N (2005). Adoptive transfer of tumour-reactive Melan-A specific T cells. J. Immunol. Vol 175 (7): 4797-4805.
[ Back to top ]
Partner 8 (Garrido)
Pattern of HLA losses in a panel of melanoma cell lines (Manuscript in preparation)
Identification of melanoma lines with interferon resistant phenotypes. (Manuscript in preparation)
[ Back to top ]
Partner 9 (Schadendorf)
Paschen A, Arens N, Sucker A, Greulich-Bode K, Fonsatti E, Gloghini A, Striegl S, Carbone A, Hildenbrand R, Maio M, Schadendorf D (2006). Instability of chromosome 15 contributes to the loss of HLA class I expression in melanoma. (Clin Cancer Res)
Partner 10 (Gaudernack)
Kyte JA, Kvalheim G, Aamdal S, Saeboe-Larssen S, Gaudernack G. (2005). Preclinical full-scale evaluation of dendritic cells transfected with autologous tumour-mRNA for melanoma vaccination. Cancer Gene Ther, 12(6):579-91.
[ Back to top ]
Partner 12 (Ball)
Lancashire, LJ, Rees, RC, Ball, GR. Neural networks identify genetic profiles that predict oestrogen receptor and lymph node status in breast cancer. (submitted)
Balls G, Quatan N, Michael A, Lancashire, L, Adams V, Hoffmann B, Pfirschke C, Russell N, Whelan MA & Pandha H (2006). Immunological response patterns correlate with clinical outcome after allogeneic vaccination in hormone resistant prostate cancer metastatic to bone. Clinical Can Res (submitted)
Lancashire, L, Ugurel, S, Creaser, C, Schadendorf, D, Rees, R, Ball, G. (2005). Utilizing Artificial Neural Networks to Elucidate Serum Biomarker Patterns Which Discriminate Between Clinical Stages in Melanoma. IEEE 2005 Symposium on Computational Intelligence in Bioinformatics and Computational Biology, Embassy Suites Hotel La Jolla, La Jolla, CA, USA. Pp: 455-460. ISBN 0-7803-9387-2
[ Back to top ]
Partner 14 (Walker)
Micheal A, Ball G, Quatan N, Wushishi F, Russell N, Whelan J, Chakraborty P, Leader D, Whelan MA & Pandha H. (2005). A prostate cancer allogeneic cell vaccine (ONY-P1) induces delayed disease progression in hormone resistant patients and correlates with immunological parameters. Clinical Can Res (in press).
[ Back to top ]